News | June 28, 2021
Lonza to expand API manufacturing facility in Nansha, China
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
